Chlamydia infection: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(27 intermediate revisions by 12 users not shown)
Line 1: Line 1:
__NOTOC__
{{DiseaseDisorder infobox |
{{DiseaseDisorder infobox |
  Name = Chlamydia |
  Name = Chlamydia |
  Image = Pap smear showing clamydia in the vacuoles 500x H&E.jpg|
  Image = Pap smear showing clamydia in the vacuoles 500x H&E.jpg|
  Caption = Pap smear showing ''C. trachomatis'' (H&E stain) |
  Caption = Pap smear showing ''C. trachomatis'' (H&E stain) - By http://visualsonline.cancer.gov/details.cfm?imageid=2331, Public Domain, https://commons.wikimedia.org/w/index.php?curid=859366 |
ICD10 = {{ICD10|A|55||a|50}}-{{ICD10|A|56|8|a|50}}, {{ICD10|A|70||a|70}}-{{ICD10|A|74|9|a|70}} |
ICD9 = {{ICD9|099.41}}, {{ICD9|483.1}} |
ICDO = |
OMIM = |
DiseasesDB = 2384 |
MedlinePlus = |
eMedicineSubj =  |
eMedicineTopic = |
MeshID = D002690 |
}}  
}}  
{{Chlamydia infection}}
{{Chlamydia infection}}
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''


{{CMG}}
{{CMG}}; {{AE}} {{Maliha}}, {{AAA}}
 
{{SK}} Chlamydial infection; Chlamydia; Sexually transmitted disease


==[[Chlamydia infection overview|Overview]]==
==[[Chlamydia infection overview|Overview]]==
Line 24: Line 19:
==[[Chlamydia infection pathophysiology|Pathophysiology]]==
==[[Chlamydia infection pathophysiology|Pathophysiology]]==


==[[Chlamydia infection epidemiology and demographics|Epidemiology & Demographics]]==
==[[Chlamydia infection causes|Causes]]==
 
==[[Chlamydia infection differential diagnosis|Differentiating Chlamydia Infection from other Diseases]]==
 
==[[Chlamydia infection epidemiology and demographics|Epidemiology and Demographics]]==


==[[Chlamydia infection risk factors|Risk Factors]]==
==[[Chlamydia infection risk factors|Risk Factors]]==
Line 30: Line 29:
==[[Chlamydia infection screening|Screening]]==
==[[Chlamydia infection screening|Screening]]==


==[[Chlamydia infection causes|Causes]]==
==[[Chlamydia infection natural history|Natural History, Complications and Prognosis]]==
 
==[[Chlamydia infection differential diagnosis|Differentiating Chlamydia infection]]==
 
==[[Chlamydia infection natural history|Complications & Prognosis]]==


==Diagnosis==
==Diagnosis==
[[Chlamydia infection history and symptoms|History and Symptoms]] | [[Chlamydia infection physical examination|Physical Examination]] | [[Chlamydia infection staging|Staging]] | [[Chlamydia infection laboratory tests|Laboratory tests]] | [[Chlamydia infection electrocardiogram|Electrocardiogram]]  | [[Chlamydia infection x ray|X Rays]] | [[Chlamydia infection CT|CT]] | [[Chlamydia infection MRI|MRI]] [[Chlamydia infection echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Chlamydia infection other imaging findings|Other images]] | [[Chlamydia infection other diagnostic studies|Alternative diagnostics]]
[[Chlamydia infection history and symptoms|History and Symptoms]] | [[Chlamydia infection physical examination|Physical Examination]] | [[Chlamydia infection laboratory tests|Laboratory Findings]] | [[Chlamydia infection ultrasound|Ultrasound]] | [[Chlamydia infection other imaging findings|Other Imaging Findings]]


==Treatment==
==Treatment==
[[Chlamydia infection medical therapy|Medical therapy]] | [[Chlamydia infection surgery|Surgical options]] | [[Chlamydia infection primary prevention|Primary prevention]]  | [[Chlamydia infection secondary prevention|Secondary prevention]] | [[Chlamydia infection cost-effectiveness of therapy|Financial costs]] | [[Chlamydia infection future or investigational therapies|Future therapies]]
[[Chlamydia infection medical therapy|Medical Therapy]] | [[Chlamydia infection surgery|Surgery]] | [[Chlamydia infection primary prevention|Primary Prevention]]  | [[Chlamydia infection secondary prevention|Secondary Prevention]] | [[Chlamydia infection cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Chlamydia infection future or investigational therapies|Future or Investigational Therapies]]
 
== Treatment ==
[[Image:ChlamydiaTrachomatisEinschlusskörperchen.jpg|thumb|right|''Chlamydia trachomatis'' inclusion bodies (brown) in a McCoy cell culture.]]
''C. trachomatis'' infection can be effectively cured with [[antibiotic]]s once it is detected. Current [[Centers for Disease Control]] guidelines provide for the following treatments:
* [[Azithromycin]] 1 gram oral as a single dose, or
* [[Doxycycline]] 100 milligrams twice daily for seven days.
* [[Tetracycline]]
* [[Erythromycin]]
Untested Treatments
* [[Ciprofloxacin]] 500 milligrams twice daily for 3 days.  (Although this is not an approved method of treatment, as it is shown to be ineffective and may simply delay symptoms.)
[[β-lactams]] are not suitable drugs for the treatment of chlamydia. While they have the ability to halt growth of the organism (i.e. are microbistatic), these antibiotics do not eliminate the bacteria. Once treatment is stopped, the bacteria will begin to grow once more.  (See below for Persistence.)
 
== Pathophysiology ==
===Chlamydial life cycle===
''Chlamydiae'' are [[obligate]] intracellular bacterial pathogens, which means they are unable to replicate outside of a host cell. However, to disseminate effectively, these pathogens have evolved a unique biphasic life cycle wherein they alternate between two functionally and morphologically distinct forms. <ref>{{cite web |url=http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mmed.section.2173 |title=Structure |accessdate=2007-10-26 |format= |work=}}</ref>
* The ''elementary body (EB)'' is infectious, but metabolically inert (much like a spore), and can survive for limited amounts of time in the extracellular milieu. Once the EB attaches to a susceptible host cell, it mediates its own internalization through pathogen-specified mechanisms (via type III secretion system) that allows for the recruitment of [[actin]] with subsequent engulfment of the bacterium.
* The internalized EB, within a membrane-bound compartment, immediately begins differentiation into the ''reticulate body (RB)''. RBs are metabolically active but non-infectious, and in many regards, resemble normal replicating bacteria. The intracellular bacteria rapidly modifies its membrane-bound compartment into the so-called chlamydial inclusion so as to prevent phagosome-lysosome fusion. According to published data, the inclusion has no interactions with the endocytic pathway and apparently inserts itself into the exocytic pathway as it retains the ability to intercept sphingomyelin-containing vesicles.
To date, no one has been able to detect a host cell protein that is trafficked to the inclusion through the exocytic pathway. As the RBs replicate, the inclusion grows as well to accommodate the increasing numbers of organisms. Through unknown mechanisms, RBs begin a differentiation program back to the infectious EBs, which are released from the host cell to initiate a new round of infection. Because of their obligate intracellular nature, ''Chlamydiae'' have no tractable genetic system, unlike [[E. coli]], which makes ''Chlamydiae'' and related organisms difficult to investigate.
 
===Persistence===
''Chlamydiae'' have the ability to establish long-term associations with host cells. When an infected host cell is starved for various nutrients such as [[amino acid]]s (e.g. [[tryptophan]]),<ref name="pmid17724071">{{cite journal |author=Leonhardt RM, Lee SJ, Kavathas PB, Cresswell P |title=Severe Tryptophan Starvation Blocks Onset of Conventional Persistence and Reduces Reactivation of Chlamydia trachomatis |journal=Infect. Immun. |volume=75 |issue=11 |pages=5105–17 |year=2007 |pmid=17724071 |doi=10.1128/IAI.00668-07}}</ref> [[iron]], or [[vitamin]]s, this has a negative consequence for ''Chlamydiae'' since the organism is dependent on the host cell for these nutrients.
The starved chlamydiae enter a persistent growth state wherein they stop cell division and become morphologically aberrant by increasing in size.<ref name="pmid16338585">{{cite journal |author=Mpiga P, Ravaoarinoro M |title=Chlamydia trachomatis persistence: an update |journal=Microbiol. Res. |volume=161 |issue=1 |pages=9–19 |year=2006 |pmid=16338585 |doi=10.1016/j.micres.2005.04.004}}</ref> Persistent organisms remain viable as they are capable of returning to a normal growth state once conditions in the host cell improve.
There is much debate as to whether persistence has in vivo relevance. Many believe that persistent chlamydiae are the cause of chronic chlamydial diseases. Some antibiotics such as β-lactams can also induce a persistent-like growth state, which can contribute to the chronicity of chlamydial diseases.
 
== Diseases caused by ''Chlamydia trachomatis'' ==
[[Image:SOA-conjunctivitis.jpg|thumb|Conjunctivitis due to chlamydia.]]
 
''[[Chlamydia trachomatis]]'' can cause the following conditions:
<div style="-moz-column-count:2; column-count:2;">
* [[Cervicitis]]
* [[Conjunctivitis]]
* [[Fitz-Hugh-Curtis syndrome]]
* [[Lymphogranuloma venereum]]
* [[Pelvic inflammatory disease]]
* [[Pneumonia]] in infants
* [[Reactive arthritis]]
* [[Urethritis]]
* Rectal infection ([[proctitis]])
* [[Prostatitis]]
* [[Ectopic pregnancy]]
</div>
 
==Recent genetic discoveries==
Recent phylogenetic studies have revealed that chlamydia shares a common ancestor with modern plants, and retains unusual plant-like traits (both [[genetics|genetically]] and [[physiology|physiologically]]). In particular, the [[enzyme]] ''L,L-diaminopimelate aminotransferase'', which is related to [[lysine]] production in plants, is also linked with the construction of chlamydia's [[cell wall]]. The genetic encoding for the enzymes is remarkably similar in plants and chlamydia, demonstrating a close common ancestry.<ref name="pmid17093042">{{cite journal |author=McCoy AJ, Adams NE, Hudson AO, Gilvarg C, Leustek T, Maurelli AT |title=L,L-diaminopimelate aminotransferase, a trans-kingdom enzyme shared by Chlamydia and plants for synthesis of diaminopimelate/lysine |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=103 |issue=47 |pages=17909–14 |year=2006 |pmid=17093042 |doi=10.1073/pnas.0608643103}}</ref>
This unexpected discovery may help scientists develop new treatment avenues: if scientists could find a safe and effective inhibitor of ''L,L-diaminopimelate aminotransferase'', they might have a highly effective and extremely specific new antibiotic against chlamydia.
 
==References==
{{reflist|2}}


== External links ==
==Case Studies==
{{commonscat|Chlamydia}}
[[Chlamydia infection case study one|Case #1]]
* [http://www.plannedparenthood.org/sexual-health/std/chlamydia.htm "Chlamydia: Questions and Answers"] from [[Planned Parenthood]]
* [http://www.netdoctor.co.uk/diseases/facts/chlamydia.htm NetDoctor Chlamydia fact sheet]
* [http://www.lib.uiowa.edu/hardin/md/chlamydiapictures.html Links to chlamydia pictures] at [[University of Iowa]]
* [http://www.chlamydiae.com/ Chlamydiae.com] - Information for [http://www.chlamydiae.com/docs/information/faq.asp patients,] as well as for [http://www.chlamydiae.com/restricted/ doctors and researchers] about Chlamydial infections.  ''Note: Patient info is in multiple languages.''


{{STD/STI}}
{{STD/STI}}
Line 119: Line 62:
[[ta:கிளமிடியா]]
[[ta:கிளமிடியா]]
[[zh:衣原體屬]]
[[zh:衣原體屬]]
[[Category:Sexually transmitted diseases]]
[[Category:Bacterial diseases]]
[[Category:Chlamydiae]]
[[Category:Infectious disease]]
[[Category:Mature chapter]]
[[Category:Gynecology]]
{{SIB}}


[[pl:Chlamydia]]
[[pl:Chlamydia]]
Line 134: Line 68:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Sexually transmitted diseases]]
[[Category:Bacterial diseases]]
[[Category:Chlamydiae]]
[[Category:Gynecology]]
[[Category:Disease]]
[[Category:Microbiology]]
[[Category:Emergency medicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Urology]]

Latest revision as of 02:34, 18 July 2021

Template:DiseaseDisorder infobox

Sexually transmitted diseases Main Page

Chlamydia infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

C. trachomatis
Other Chlamydiae

Differentiating Chlamydia Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chlamydia infection On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chlamydia infection

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chlamydia infection

CDC on Chlamydia infection

Chlamydia infection in the news

Blogs on Chlamydia infection

Directions to Hospitals Treating Chlamydia infection

Risk calculators and risk factors for Chlamydia infection

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maliha Shakil, M.D. [2], Aysha Aslam, M.B.B.S[3]

Synonyms and keywords: Chlamydial infection; Chlamydia; Sexually transmitted disease

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Chlamydia Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Ultrasound | Other Imaging Findings

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Template:STD/STI Template:Bacterial diseases

ar:كلاميديا da:Klamydia de:Chlamydien it:Infezioni da clamidia he:כלמידיה mk:Хламидија ms:Penyakit kelamin Chlamydia nl:Chlamydia no:Klamydia-infeksjon sl:Klamidioza fi:Klamydia sv:Klamydia ta:கிளமிடியா


Template:WikiDoc Sources